News
Read all about our latest news.
Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Our Head of Development, Sheryl Caswell is featured in the CCRA Yearbook discussing the impact of digital biomarkers on clinical research
Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Our Head of Development, Sheryl Caswell is featured in the CCRA Yearbook discussing the impact of digital biomarkers on clinical research
Contact Us
We believe that neuroscience will be in the next decade what oncology has been in the last.
